Serum leptin, adiponectin, resistin and ghrelin levels in psoriatic patients treated with cyclosporin.
Cyclosporin has various effects on adipose tissue and glucose metabolism. This situation may lead to changes in serum levels of adipocyte-derived cytokines which have influence on the pathogenesis of psoriasis. The aim of this study was to evaluate the effect of cyclosporin treatment on some adipocyte-derived cytokines in psoriatic patients. This case-control study was performed between June 2009 and March 2010, at the Department of Dermatology of Meram School of Medicine. Serum leptin, adiponectin, resistin and ghrelin levels were assessed in 26 patients with psoriasis before and after cyclosporin treatment and body mass index-matched 26 healthy control subjects. The adipokines levels were compared between the groups. Serum leptin, ghrelin, resistin and adiponectin levels in patients with psoriasis before the treatment were higher than those of the control group but the differences were not statistically significant. A positive correlation between serum leptin and family history of psoriasis was detected (r = 0.398, P = 0.044). A strong negative correlation between the Psoriasis Area and Severity Index and serum ghrelin levels was seen (r = -0.52, P = 0.001) and there was a strong positive correlation between the Nail Psoriasis Severity Index and serum resistin levels (r = 0.62, P = 0.001). Following the treatment, a significant increase was seen in the serum level of adiponectin (P = 0.02) and resistin (P = 0.003). The correlations between the adipokines and the disease parameters before the treatment were lost after the treatment. Our results suggest that levels of some adipocyte-derived cytokines in psoriatic patients are affected by cyclosporin treatment.
Department of Dermatology, School of Medicine, Bezmialem Vakif University, Istanbul, Turkey. mustafaozdemir@yahoo.com
Mustafa
M
Ozdemir
Mavişe
M
Yüksel
Hakkı
H
Gökbel
Nilsel
N
Okudan
Inci
I
Mevlitoğlu
D054392:Adipokines / Q000097:blood*; D052242:Adiponectin / Q000097:blood; D000328:Adult; D016022:Case-Control Studies; D016572:Cyclosporine / Q000627:therapeutic use*; D005260:Female; D054439:Ghrelin / Q000097:blood; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D020738:Leptin / Q000097:blood; D008297:Male; D008875:Middle Aged; D011565:Psoriasis / Q000097:blood* / Q000188:drug therapy*; D052243:Resistin / Q000097:blood
C499918:ADIPOQ protein, human; D054392:Adipokines; D052242:Adiponectin; D054439:Ghrelin; D007166:Immunosuppressive Agents; D020738:Leptin; C499624:RETN protein, human; D052243:Resistin; D016572:Cyclosporine